Hormone refractory breast cancer

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Antibody-drug conjugate (ADC) 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Reinier de Graaf Groep Academic
    IMP not specified
    2023-507847-13-00 1 country 2024 n=67
    Recruiting

Phase II

1 trial
  • AstraZeneca AB Commercial
    DATOPOTAMAB DERUXTECAN
    2025-521904-23-00 3 countries 2026 n=50
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 1 Phase II 1
Reinier de Graaf Groep Academic 1 Phase III 1
New trials by year
2024
1
2026
1
← All indication landscapes